Gerresheimer’s €9.7 Million Insider Spree Meets a Skeptical Market
14.05.2026 - 23:30:56 | boerse-global.de
When a company’s own insiders splash out nearly €10 million on shares in a single week, it usually sends a powerful signal. In Gerresheimer’s case, the market is barely listening. The stock closed at €25.20 on Thursday, down almost 5% on the day, and has shed about 60% over the past year despite a recent bounce. The disconnect between insider confidence and investor sentiment has rarely been starker.
The buying came from AOC Gecko S.à r.l., a vehicle tied to major shareholder Active Ownership, which snapped up roughly 287,000 shares in three tranches during the first week of May. Prices ranged from €24.99 to €25.85, putting the total outlay at around €9.73 million — the largest insider transaction recorded in Germany over the period. Active Ownership now holds more than 15% of Gerresheimer’s equity, strengthening its grip on the company at a moment when its credibility is under intense scrutiny.
That scrutiny stems from a series of accounting failures that came to light late last year. An external law firm confirmed that Gerresheimer had systematically misapplied IFRS rules by booking revenue under so-called bill-and-hold arrangements where goods were invoiced to customers but delivered much later. The irregularities hit revenue by €35 million and adjusted operating profit by €24 million. The company has since announced non-cash impairments of €220 million to €240 million for the 2025 financial year, primarily tied to technology projects at Sensile Medical AG and the now-shuttered Chicago Heights plant, which will close by year-end with production moving to Italy and India.
Should investors sell immediately? Or is it worth buying Gerresheimer?
Bears are circling. Gerresheimer’s short interest stands at 14.95% of issued shares, far above its 12-month average of 5.80%. Arrowstreet Capital trimmed its net short position slightly to 1.99%, but the broader hedge fund community remains heavily entrenched — a remarkable level of negative conviction for a mid-cap German industrial. Still, the shorts have not had it all their own way: the stock has jumped roughly 44% over the past month, a relief rally fueled partly by the insider purchases and partly by a crucial lifeline from creditors.
That lifeline came when holders of 96% of Gerresheimer’s €870 million Schuldschein loan agreed to extend the maturity to September 2026 and suspend key leverage covenants. The move buys time, but the clock is still ticking. The audited annual financial statements are due in June 2026, followed shortly by the first-quarter report, and then the half-year results on July 14. Each milestone offers a chance to restore — or further erode — trust.
On the asset side, Gerresheimer plans to sell its US subsidiary Centor, which had a book value of €292 million at the end of 2024. Management aims to complete the divestiture this year. For 2026, it guides revenue between €2.3 billion and €2.4 billion with an adjusted EBITDA margin of 18% to 19%. Whether those targets hold water depends on the numbers the auditors ultimately sign off on. The June audit is shaping up to be the next major catalyst — and a true test of whether the insiders’ €9.7 million bet was prescient or premature.
Ad
Gerresheimer Stock: New Analysis - 14 May
Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Gerresheimer’s Aktien ein!
FĂĽr. Immer. Kostenlos.
